ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Autoantibody(ies)"

  • Abstract Number: L11 • ACR Convergence 2024

    Rheumatology Diagnostics Utilizing Artificial Intelligence (ANA Reader©) for ANA Pattern Identification and Titer Quantification

    May Choi1, Farbod Moghaddam1, Mohammad Sajadi1, Ann E. Clarke1, Sasha Bernatsky2, Karen Costenbader3, Irene Chen4, Murray Urowitz5, John Hanly6, Caroline Gordon7, Sang-Cheol Bae8, Juanita Romero-Diaz9, Jorge Sanchez-Guerrero10, Daniel Wallace11, David Isenberg12, Anisur Rahman13, Joan Merrill14, Paul Fortin15, Dafna Gladman16, Ian Bruce17, Michelle Petri18, Ellen Ginzler19, Mary Anne Dooley20, Rosalind Ramsey-Goldman21, Susan Manzi22, Andreas Jönsen23, Graciela Alarcón24, Ronald Van Vollenhoven25, Cynthia Aranow26, Meggan Mackay26, Guillermo Ruiz-Irastorza27, S. Sam Lim28, Murat Inanç29, Kenneth Kalunian30, Soren Jacobsen31, Christine Peschken32, Diane Kamen33, Anca Askanase34, Marvin Fritzler35 and Mina Aminghafari1, 1University of Calgary, Calgary, AB, Canada, 2Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 3Brigham and Women's Hospital/Harvard Medical School, Boston, MA, 4UC Berkeley and UCSF, Berkeley, CA, 5Self employed, Toronto, ON, Canada, 6Dalhousie University, Halifax, NS, Canada, 7University of Birmingham, Birmingham, United Kingdom, 8Hanyang University Medical Center, Seoul, South Korea, 9The National Institute of Medical Sciences and Nutrition, Mexico City, Mexico, 10Krembil Research Institute, Toronto, ON, Canada, 11Cedars Sinai Medical Center, Studio City, CA, 12Department of Ageing, Rheumatology and Regenerative Medicine, Division of Medicine, University College London, London, United Kingdom, 13University College London, London, United Kingdom, 14Oklahoma Medical Research Foundation, Oklahoma City, OK, 15Centre ARThrite - CHU de Québec - UniversitéLaval, Quebec, QC, Canada, 16University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 17Queen's University Belfast, Belfast, United Kingdom, 18Johns Hopkins University School of Medicine, Baltimore, MD, 19SUNY Downstate Health Sciences University, New York, NY, 20UNC physician network, Chapel Hill, NC, 21Northwestern University, Chicago, IL, 22Allegheny Health Network, Pittsburgh, PA, 23Lund University, Lund, Sweden, 24The University of Alabama at Birmingham, Oakland, CA, 25Amsterdam UMC, Amsterdam, Netherlands, 26Feinstein Institutes for Medical Research, New York, NY, 27Biobizkaia Health Research Institute, Bilbao, Spain, 28Emory University, Atlanta, GA, 29Istanbul University, Istanbul, Turkey, 30UC San Diego, La Jolla, CA, 31Rigshospitalet, Copenhagen, Denmark, 32University of Manitoba, Winnipeg, MB, Canada, 33Medical University of South Carolina, Johns Island, SC, 34Columbia University Medical Center, New York, NY, 35Mitogen Diagnostics Corp, Calgary, AB, Canada

    Background/Purpose: Antinuclear antibody (ANA) immunofluorescence (IFA) patterns and titers are a key part of rheumatology diagnostics, however, there is considerable intra- and inter-laboratory variability with…
  • Abstract Number: 0151 • ACR Convergence 2024

    Immunoproteomic Profiling of Antibodies in Autoimmune Diseases

    Choa Yun1, Ji Qiu2, M. Constanza Camargo3, Lusheng Song2, Joshua LaBaer2, Hyokyoung G. Hong3, Eric A. Engels3, Maddy Edie-Booker4, Adam Schiffenbauer5, Lisa Rider6, Frederick Miller7, Sarfaraz Hasni5, Blake M. Warner5, Mārcis Leja8 and Minkyo Song9, 1National Institute on Aging, Rockville, MD, 2Arizona State University, Tempe, 3National Cancer Institute, Rockville, 4National Institute on Aging, Baltimore, MD, 5NATIONAL INSTITUTES OF HEALTH, Bethesda, MD, 6NIEHS, NIH, Garrett Park, MD, 7NIH, NIEHS, Chapel Hill, NC, 8University of Latvia, Rīga, Latvia, 9National Institutes on Aging, Baltimore, MD

    Background/Purpose: Prior research has investigated a limited range of candidate markers within individual autoimmune diseases. This study aimed to identify specific and common autoantibodies and…
  • Abstract Number: 0627 • ACR Convergence 2024

    Clinical Conditions Associated with Presence of a High-titer Antinuclear Antibody in Individuals Without Autoimmune Disease

    Matthew Chung1, John Shelley2, John Still2, Gul Karakoc3, Xiaodi Ruan4, Jonathan D. Mosley4, C. Michael Stein4 and Vivian K. Kawai4, 1VU, Nashville, TN, 2VUMC, Nashville, TN, 3Vanderbilt University Medical Center, Mt. Pleasant, SC, 4Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Antinuclear antibodies (ANAs) are a diverse group of autoantibodies that are commonly present in SLE and other autoimmune (AI) disorders. However, a positive ANA…
  • Abstract Number: 1146 • ACR Convergence 2024

    Impact of COVID-19 on Myositis Testing Trends

    Angel Kevin Garza-Elizondo1, Rosa Icela Arvizu-Rivera2, Pablo Gamez-Siller3, Daniela Alejandra Salcedo-Soto4, Jesus Cardenas-de la Garza5, Gisela Garcia-Arellano6, Miguel Angel Villarreal-Alarcon2 and Dionicio Galarza-Delgado7, 1Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, 2Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 3Facultad de Medicina UANL, Monterrey, Nuevo León, Mexico, 4Hospital Universitario Dr Jose Eleuterio Gonzalez, Monterrey, Mexico, 5Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, 6Hospital Universitario \"Dr. José Eleuterio González\", Monterrey, Nuevo León, Mexico, 7UANL Hospital Universitario, Monterrey, Nuevo León, Mexico

    Background/Purpose: Idiopathic inflammatory myopathies (IIM), also known as myositis, are a group of heterogeneous autoimmune disorders that lead to muscle injury. Autoantibodies help make the…
  • Abstract Number: 1561 • ACR Convergence 2024

    Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension

    Brett Dinner1, Ahmed Abdelmaksoud2, Ann Igoe3, Taylor Viggiano4 and Vivek Nagaraja5, 1Creighton University, Paradise Valley, AZ, 2University of California, Riverside, Riverside, CA, 3Flow, Tempe, AZ, 4Mayo Clinic, Phoenix, 5Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…
  • Abstract Number: 1788 • ACR Convergence 2024

    Memory B Cell Activation and Dysregulation in Systemic Lupus Erythematosus

    Shady Younis1, Salvinaz Moutusy2, Shaghayegh Jahanbani2, Xiaohao Wu2, Marlayna Harris2, Mahesh Pandit3, Laura van Dam4, orr Sharpe5, Paul Utz1 and William Robinson6, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Stanford, 3Stanford University School of Medicine, Stanofrd, 4Stanford, Palo Alto, CA, 5Department of Immunology and Rheumatology, Stanford University, Stanford, CA, 6Division of Immunology and Rheumatology, Stanford University, and VA Palo Alto Health Care System, Stanford, CA

    Background/Purpose: B cell dysregulation and production of autoantibodies against autoantigens are hallmarks of Systemic lupus erythematosus (SLE). In healthy adults (HC), B cells with autoreactive…
  • Abstract Number: 2233 • ACR Convergence 2024

    Maximizing Diagnostic Sensitivity: Combined Anti-RA33, Anti-CarP, and Anti-PAD4 Autoantibodies in Seronegative Rheumatoid Arthritis

    Andrew Concoff1, Touba Warsi2, Sepehr Taghavi2, Sudha Kumar2, Abigail Patalinghug2, Christine Schleif2, Brittany Partain3, Joseph Ahearn4, Susan Manzi5, Michael Mahler6, Veena Joy7 and Tyler O'Malley8, 1Exagen, Inc., Los Angeles, CA, 2Exagen, Carlsbad, CA, 3Exagen, Boston, MA, 4Allegheny Health Network, Wexford, PA, 5Allegheny Health Network, Pittsburgh, PA, 6Werfen, San Diego, CA, 7ThermoFisher, Philadelphia, PA, 8Exagen, Vista, CA

    Background/Purpose: Studies have found autoantibodies (Ab) directed against heterogeneous nuclear ribonucleoprotein A2/B1 (anti-RA33), peptidyl arginine deiminase 4 (anti-PAD4) and carbamylated proteins (anti-CarP) each have diagnostic…
  • Abstract Number: 2668 • ACR Convergence 2024

    Do Levels of anti-Jo1 Autoantibodies Have a Prognostic Role? Longitudinal Assessment of anti-Jo1 and HisRS Protein Levels in a Cohort of anti-Jo1 Positive Patients with Anti-synthetase Syndrome

    Silvia Cavalli1, Fabricio Espinosa-Ortega2, Ryan A. Adams3, Lauren Guy3, Charlotta Preger4, Càtia Fernandes-Cerqueira5, Roberto Caporali6, Ingrid Lundberg7 and Antonella Notarnicola8, 1University of Milan, Milan, Milan, Italy, 2Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet; Department of Gastro, Dermatology and Rheumatology, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 3aTyr Pharma, 3545 John Hopkins Court, Suite 250, San Diego, CA, 4Division of Rheumatology, Department of Medicine, Solna, Karolinska Institutet;5Structural Genomics Consortium, Stockholm, Sweden, Stockholm, Stockholms Lan, Sweden, 54Dcell, Montrueil, Ile-de-France, France, 6Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, 7Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 8Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden

    Background/Purpose: The anti-Jo1 autoantibody (aJo1), targeting the histidyl-tRNA synthetase (HisRS) protein, is the most common diagnostic biomarker of the anti-synthetase syndrome (ASSD). So far, conflicting…
  • Abstract Number: 0158 • ACR Convergence 2024

    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023

    Karis Lee1, Min Kyung Lee2, David Alfego3, Kristen Clark4 and Stanley Naides5, 1Labcorp, Orlando, FL, 2Labcorp, San Diego, CA, 3Labcorp, Carlsbad, CA, 4Labcorp, Raleigh, NC, 5Labcorp, Dana Point, CA

    Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
  • Abstract Number: 0629 • ACR Convergence 2024

    Evaluating the Concordance Between SRI4 and BICLA Using Placebo Data from Randomized Controlled Trials of Patients with Active Systemic Lupus Erythematosus

    Anca Askanase1, Edward Vital2, Oliver Meier3, Armando Turchetta4, Huiyan (Ashley) Mao4, Justine Maller5, Jorge A. Ross Terres6 and Maria Dall'Era7, 1Columbia University Medical Center, New York, NY, 2Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc,, San Francisco, CA, 6Genentech, Inc,, San Francisco, 7UCSF, Corte Madera, CA

    Background/Purpose: British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI4) responses are the most common primary…
  • Abstract Number: 1150 • ACR Convergence 2024

    Increased ISG15 Expression in Peripheral Blood from Patients with Positive Dermatomyositis Related Specific Autoantibodies

    Sylvia Raftopoulou1, Nikolaos Michalakeas1, Maria Gerochristou2, Nikolaos Marketos1, Charalampos Skarlis1 and Clio Mavragani3, 1Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, 2Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, 3Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterised by muscle inflammation (myositis) and weakness, impacting various organ systems. Clinical subtypes include dermatomyositis (DM), antisynthetase syndrome (ASyS),…
  • Abstract Number: 1562 • ACR Convergence 2024

    Autoantibody Associations with Disease Manifestations in Patients with Early Diffuse Cutaneous Systemic Sclerosis: The Prospective Registry of Early Systemic Sclerosis

    Aradhna Agarwal1, Dahlia Hassan2, Suiyuan Huang3, Flavia Castelino4, Shervin Assassi5, Robyn Domsic6, Tracy Frech7, Jessica Gordon8, Faye Hant9, Monique Hinchcliff10, Ami Shah11, Victoria Shanmugam12, Virginia Steen13, Dinesh Khanna3 and Elana Bernstein14, 1Columbia University, New York, NY, 2Hospital for Special Surgery, New York, NY, 3University of Michigan, Ann Arbor, MI, 4Massachusetts General Hospital, Boston, MA, 5UTHealth Houston Division of Rheumatology, Houston, TX, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 7Vanderbilt University Medical Center, Nashville, TN, 8Division of Rheumatology, Weill Cornell Medical College, New York, NY, 9Medical University of South Carolina, Charleston, SC, 10Yale School of Medicine, Westport, CT, 11Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, 12NIH Office of Autoimmune Disease Research in the Office of Research on Women's Health, National Institutes of Health, Bethesda, MD, Bethesda, MD, 13Georgetown University School of Medicine, Washington, DC, 14Columbia University Irving Medical Center, New York, NY

    Background/Purpose: Several autoantibodies have been linked to various disease manifestations of systemic sclerosis (SSc). Anti-RNA polymerase 3 (ARA) and anti-topoisomerase-I (ATA) are both associated with…
  • Abstract Number: 1792 • ACR Convergence 2024

    CD14+ Monocytes Demonstrate Subclinical Erythrocyte Uptake in Childhood Onset Systemic Lupus Erythematosus

    Lauren Robinson1, Preetha Balasubramanian2, Zurong Wan2, Juan Rodriguez Alcazar2, Marina Lima Silva Santos2, Lynnette Walters3, Jeanine Baisch2, Karen Onel4, Tracey Wright5, Virginia Pascual6 and Simone Caielli2, 1Hospital for Special Surgery, New York, NY, 2Weill Cornell Medicine, New York, NY, 3Scottish Rite Hospital for Children, Allen, TX, 4HSS, New York, NY, 5UT Southwestern, Plano, TX, 6Weill Cornell Medical College, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a disease characterized by the presence of auto-antibodies, immune complex deposition, and a robust type I interferon (IFN) signature.…
  • Abstract Number: 2294 • ACR Convergence 2024

    Pharmacodynamic Effects of Nipocalimab on Disease Biomarkers in Patients with Moderate-to-Severe Active Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2 Study

    Kathy Sivils1, Steven Leonardo2, He Li3, Keying Ma4, Matthew J. Loza5, Jonathan J. Hubbard4, Kim Campbell4 and Sheng Gao4, 1Johnson & Johnson Innovative Medicine, Edmond, OK, 2Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, 3Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 4Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, 5Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

    Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that selectively binds to the IgG-binding site of the neonatal crystallizable fragment receptor…
  • Abstract Number: 2669 • ACR Convergence 2024

    Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies

    Hannah Bulgart1, Kassidy Banford2, Shane Bruckner3, Kevin McElhanon2, Nicholas Young1, Brian Paleo2, Eric Beck2, Rohit Aggarwal4, Chester Oddis5, Braden Zeno6, Wael Jarjour7 and Noah Weisleder3, 1The Ohio State University Wexner Medical Center, Columbus, OH, 2The Ohio State University, Columbus, 3Ohio State University, Columbus, OH, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Ohio State University, upper arlington, OH, 7The Ohio State University, Columbus, OH

    Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
  • 1
  • 2
  • 3
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology